Return to Today's science sparks archives

2014-01-02

Fig 1. Evolution of sunscreens from predominant protection against UVB light toward spectral homeostasis (E1,1, extinction at 1-cm path length and 1% concentration as a measure for UV light filter efficacy at every wavelength in the UVR range). UV, Ultraviolet; UVB, ultraviolet B; UVR, ultraviolet radiation.

Fig 1. Evolution of sunscreens from predominant protection against UVB light toward spectral homeostasis (E1,1, extinction at 1-cm path length and 1% concentration as a measure for UV light filter efficacy at every wavelength in the UVR range). UV, Ultraviolet; UVB, ultraviolet B; UVR, ultraviolet radiation.
  • Jansen R, Osterwalder U, Wang SQ, Burnett M, Lim HW

  • J Am Acad Dermatol. 2013 Dec;69(6):867.e1-867.e14.

2014-01-03

Fig 1. Pelvic control as a function of stage.

Fig 1. Pelvic control as a function of stage.
  • Desai NB, Kiess AP, Kollmeier MA, Abu-Rustum NR, Makker V, Barakat RR, Alektiar KM

  • Gynecol Oncol. 2013 Dec;131(3):604-8.

2014-01-06

Fig 1a. Endoscopy with retrovision shows a distal tumor, just above the levator.

Fig 1a. Endoscopy with retrovision shows a distal tumor, just above the levator.
  • Weiser MR, Beets-Tan R, Beets G

  • Surg Oncol Clin N Am. 2014 Jan;23(1):113-25.

2014-01-07

Fig 2. Transformation results in alterations of mRNA levels and in changes of 3′ UTR length in different groups of genes that function in the same biological processes.

Fig 2. Transformation results in alterations of mRNA levels and in changes of 3′ UTR length in different groups of genes that function in the same biological processes.
  • Lianoglou S, Garg V, Yang JL, Leslie CS, Mayr C

  • Genes Dev. 2013 Nov 1;27(21):2380-96.
Open Access button

2014-01-08

Fig 1. Number of patients undergoing pancreatic metastasectomy at MSKCC from 1993 to 2012. An increase in the number of resections is noted over time with a lower percentage of patients with RCC in recent years. Values represent sums of 2-year intervals.

Fig 1. Number of patients undergoing pancreatic metastasectomy at MSKCC from 1993 to 2012. An increase in the number of resections is noted over time with a lower percentage of patients with RCC in recent years. Values represent sums of 2-year intervals.
  • Untch BR, Allen PJ

  • J Surg Oncol. 2014 Jan;109(1):28-30.

2014-01-09

Fig 1.MicroRNA processing pathway.

Fig 1.MicroRNA processing pathway.
  • Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM

  • Urol Oncol. 2014 Jan;32(1):41.e31-40.

2014-01-10

Fig 2. Histopathological phenotype of MCN-like lesions.  (B) High-power view of cyst in panel A reveals dense ovarian-like stroma, and cuboidal epithelium that lacks abundant mucin production.

Fig 2. Histopathological phenotype of MCN-like lesions. (B) High-power view of cyst in panel A reveals dense ovarian-like stroma, and cuboidal epithelium that lacks abundant mucin production.
  • Sano M, Driscoll DR, De Jesus-Monge WE, Klimstra DS, Lewis BC

  • Gastroenterology. 2014 Jan;146(1):257-67.

2014-01-13

Fig 1. Local recurrence-free survival for 1,076 patients undergoing surgical resection for retroperitoneal sarcoma between 1982 and 2012.

Fig 1. Local recurrence-free survival for 1,076 patients undergoing surgical resection for retroperitoneal sarcoma between 1982 and 2012.
  • Gyorki DE, Brennan MF

  • J Surg Oncol. 2014 Jan;109(1):53-9.

2014-01-14

Fig 3. Cumulative incidence plot for death caused by solid cancers 5 years after diagnosis in patients with germ cell tumors (n = 37,283).

Fig 3. Cumulative incidence plot for death caused by solid cancers 5 years after diagnosis in patients with germ cell tumors (n = 37,283).
  • Alanee SR, Feldman DR, Russo P, Konety B

  • Urol Oncol. 2014 Jan;32(1):26.e9-26.e15.

2014-01-15

Fig 1. a: If mutation testing reveals clones with primary imatinib resistance (e.g., KIT exon 17 mutation), sunitinib, surgery or other treatment modalities should be considered. b: PET scan in setting of equivocal CT findings or patients with IV contrast allergies. c: If all gross disease or all imatinib resistant disease is treatable.

Fig 1. a: If mutation testing reveals clones with primary imatinib resistance (e.g., KIT exon 17 mutation), sunitinib, surgery or other treatment modalities should be considered. b: PET scan in setting of equivocal CT findings or patients with IV contrast allergies. c: If all gross disease or all imatinib resistant disease is treatable.
  • Bamboat ZM, DeMatteo RP

  • J Surg Oncol. 2014 Jan;109(1):23-7.

2014-01-16

Fig 1. Sugarbaker's peritoneal cancer index (PCI). PCI is determined by assigning a LSS to each of the 13 peritoneal regions and then summing the scores.

Fig 1. Sugarbaker's peritoneal cancer index (PCI). PCI is determined by assigning a LSS to each of the 13 peritoneal regions and then summing the scores.
  • Kelly KJ, Nash GM

  • J Surg Oncol. 2014 Jan;109(1):14-22.

2014-01-17

Fig 1. Trial profile.

Fig 1. Trial profile.
  • Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ

  • Lancet Oncol. 2013 Dec;14(13):1307-16.

2014-01-20

Fig 1. Areas of Research Specialization.

Fig 1. Areas of Research Specialization.
  • Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M

  • Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):11-7.

2014-01-21

Fig 1.Representative γ images for intensity modulated radiation therapy prostate, brain, and lung patients. The sharp edge in the stripe of failing pixels in the brain field in the second row indicates that part of the linear accelerator couch may be interfering with the transit measurement.

Fig 1.Representative γ images for intensity modulated radiation therapy prostate, brain, and lung patients. The sharp edge in the stripe of failing pixels in the brain field in the second row indicates that part of the linear accelerator couch may be interfering with the transit measurement.
  • Berry SL, Polvorosa C, Cheng S, Deutsch I, Chao KS, Wuu CS

  • Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):204-9.

2014-01-22

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
  • Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, Fisher S, Viñuela EF, Kingham TP, Fong Y, Dematteo RP, D'Angelica MI, Jarnagin WR, Allen PJ

  • J Am Coll Surg. 2014 Jan;218(1):129-39.

2014-01-23

Fig 1. Layers of the rectal wall on endorectal ultrasound imaging.

Fig 1. Layers of the rectal wall on endorectal ultrasound imaging.
  • Samdani T, Garcia-Aguilar J

  • Surg Oncol Clin N Am. 2014 Jan;23(1):59-77.

2014-01-24

Fig 1. Schematic of the mouse Oprm1 gene and the MOR-1 splice variants.

Fig 1. Schematic of the mouse Oprm1 gene and the MOR-1 splice variants.
  • Pasternak GW

  • Neuropharmacology. 2014 Jan;76 Pt B:198-203.

2014-01-27

Fig 1. Modified Muller Nuremberger scale showing different grades of cellulite.

Fig 1. Modified Muller Nuremberger scale showing different grades of cellulite.
  • Rossi AM, Katz BE

  • Dermatol Clin. 2014 Jan;32(1):51-9.

2014-01-28

Fig 1. The cumulative incidence of total bilirubin ≥1.5 × ULN by predicted UGT1A1 function in pazopanib- or sunitinib-treated patients.

Fig 1. The cumulative incidence of total bilirubin ≥1.5 × ULN by predicted UGT1A1 function in pazopanib- or sunitinib-treated patients.
  • Motzer RJ, Johnson T, Choueiri TK, Deen KC, Xue Z, Pandite LN, Carpenter C, Xu CF

  • Ann Oncol. 2013 Nov;24(11):2927-8.

2014-01-29

Fig 1. Cumulative staging information for STIC cases identified with RRSO.

Fig 1. Cumulative staging information for STIC cases identified with RRSO.
  • Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ

  • Int J Gynecol Cancer. 2013 Nov;23(9):1603-11.

2014-01-30

Fig 1. Heuristic model of bi-directional relationships between cognitive deficits and self-regulatory challenge following cancer.

Fig 1. Heuristic model of bi-directional relationships between cognitive deficits and self-regulatory challenge following cancer.
  • Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA

  • Psychooncology. 2014 Jan;23(1):1-8.

2014-01-31

Fig 1. Techniques of margin assessment.

Fig 1. Techniques of margin assessment.
  • Moo TA, Choi L, Culpepper C, Olcese C, Heerdt A, Sclafani L, King TA, Reiner AS, Patil S, Brogi E, Morrow M, Van Zee KJ

  • Ann Surg Oncol. 2014 Jan;21(1):86-92.

2014-02-03

Fig 1. Nonrelapse mortality and overall survival.

Fig 1. Nonrelapse mortality and overall survival.
  • Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Iori AP, Horowitz MM, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V; Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation

  • Blood. 2014 Jan 2;123(1):133-40.

2014-02-04

Fig 3d. Enhanced Impact of NB2 Loss on High-Density GABApre-Sensory Synapses. Optimized transition matrix for the NB2 mutant.

Fig 3d. Enhanced Impact of NB2 Loss on High-Density GABApre-Sensory Synapses. Optimized transition matrix for the NB2 mutant.
  • Ashrafi S, Betley JN, Comer JD, Brenner-Morton S, Bar V, Shimoda Y, Watanabe K, Peles E, Jessell TM, Kaltschmidt JA

  • Neuron. 2014 Jan 8;81(1):120-9.

2014-02-05

Fig 2. A series of shell structures is created to account for shrinkages from the original to predicted residual planning target volume (PTV).

Fig 2. A series of shell structures is created to account for shrinkages from the original to predicted residual planning target volume (PTV).
  • Zhang P, Yorke E, Hu YC, Mageras G, Rimner A, Deasy JO

  • Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):446-52.

2014-02-06

Fig 2.Prostate apex examined with the cone method. (A) The arrow indicates an area of the inked surface suspicious for positive surgical margin in the hematoxylin and eosin–stained section.

Fig 2.Prostate apex examined with the cone method. (A) The arrow indicates an area of the inked surface suspicious for positive surgical margin in the hematoxylin and eosin–stained section.
  • Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, Touijer K

  • Eur Urol. 2014 Feb;65(2):303-13.

2014-02-07

Fig 1. Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival in early versus late responders to sunitinib

Fig 1. Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival in early versus late responders to sunitinib
  • Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, Motzer RJ

  • Eur J Cancer. 2014 Jan;50(2):351-8.

2014-02-10

Fig 1. Structure of the KIT protein.

Fig 1. Structure of the KIT protein.
  • Carvajal RD, Hamid O, Antonescu CR

  • Methods Mol Biol. 2014;1102:137-62.

2014-02-11

Fig 1.Mechanisms of resistance to RAF inhibitors.

Fig 1.Mechanisms of resistance to RAF inhibitors.
  • Solit DB, Rosen N

  • Cancer Discov. 2014 Jan;4(1):27-30.

2014-02-12

Enrichment of SSRP1 over Genes that Expression Is Regulated by NF-κB.

Enrichment of SSRP1 over Genes that Expression Is Regulated by NF-κB.
  • Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C, Gurova KV

  • Cell Rep. 2013 Jul 11;4(1):159-73.
Open Access button

2014-02-13

Targeting immune checkpoints with CTLA-4 and PD-1 blocking antibodies in cancer immunotherapy.

Targeting immune checkpoints with CTLA-4 and PD-1 blocking antibodies in cancer immunotherapy.
  • Kyi C, Postow MA

  • FEBS Lett. 2014 Jan 21;588(2):368-76.

2014-02-14

Structural models and binding affinities of murine anti-GD2 monoclonal antibodies.

Structural models and binding affinities of murine anti-GD2 monoclonal antibodies.
  • Ahmed M, Cheung NK

  • FEBS Lett. 2014 Jan 21;588(2):288-97.

2014-02-18

Fig 1. Study schema is shown. q2w indicates every 2 weeks; qw, every week; q3w, every 3 weeks; MUGA, multigated acquisition.

Fig 1. Study schema is shown. q2w indicates every 2 weeks; qw, every week; q3w, every 3 weeks; MUGA, multigated acquisition.
  • Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT

  • Cancer. 2013 Aug 26.

2014-02-19

Fig 1.(A) Prostatectomy specimen with a confined tumor with a positive margin due to capsular incision (pT2). (B) Extraprostatic extension with a positive surgical margin (pT3).

Fig 1.(A) Prostatectomy specimen with a confined tumor with a positive margin due to capsular incision (pT2). (B) Extraprostatic extension with a positive surgical margin (pT3).
  • Meeks JJ, Eastham JA

  • Urol Oncol. 2013 Oct;31(7):974-9

2014-02-20

Fig 2. In vitro quantification of viral replication by GLV-1 h153 in human gastric cancer cell lines.

Fig 2. In vitro quantification of viral replication by GLV-1 h153 in human gastric cancer cell lines.
  • Jun KH, Gholami S, Song TJ, Au J, Haddad D, Carson J, Chen CH, Mojica K, Zanzonico P, Chen NG, Zhang Q, Szalay A, Fong Y

  • J Exp Clin Cancer Res. 2014 Jan 2;33(1):2.
Open Access button

2014-02-21

Fig 1. Representative histologic images of tumors with complex glandular patterns.

Fig 1. Representative histologic images of tumors with complex glandular patterns.
  • Moreira AL, Joubert P, Downey RJ, Rekhtman N

  • Hum Pathol. 2014 Feb;45(2):213-20.

2014-02-24

Fig 1. Factors predisposing the elderly to sepsis. Elderly individuals are vulnerable to the development of severe, life-threatening infections for multifactorial reasons.

Fig 1. Factors predisposing the elderly to sepsis. Elderly individuals are vulnerable to the development of severe, life-threatening infections for multifactorial reasons.
  • Lineberry C, Stein DE

  • Crit Care Nurs Clin North Am. 2014 Mar;26(1):47-60.

2014-02-25

Fig 1. Waterfall plot of best change from baseline in tumour response, according to histology.

Fig 1. Waterfall plot of best change from baseline in tumour response, according to histology.
  • Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G

  • Lancet Oncol. 2014 Feb;15(2):191-200.

2014-02-26

Fig 1. Kaplan Meier curves of persistence on protocol in patients with tumors showing H2T/p95 expression ratio values higher (solid line) or equal/lower (dotted line) than the median value of 46.60.

Fig 1. Kaplan Meier curves of persistence on protocol in patients with tumors showing H2T/p95 expression ratio values higher (solid line) or equal/lower (dotted line) than the median value of 46.60.
  • Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P, Sapino A, Aglietta M, Baselga J, Scaltriti M

  • Mol Oncol. 2014 Feb;8(1):20-6.

2014-02-27

Fig 1. Schematic diagram to illustrate the DDM concept. Voxels at locations Xj, Xk, Xl in the images [j], [k] and [l] that are co-registered at the same voxel Xi in image [i] (dashed lines) are typically registered at different locations in another image [m] (dotted lines).

Fig 1. Schematic diagram to illustrate the DDM concept. Voxels at locations Xj, Xk, Xl in the images [j], [k] and [l] that are co-registered at the same voxel Xi in image [i] (dashed lines) are typically registered at different locations in another image [m] (dotted lines).
  • Saleh ZH, Apte AP, Sharp GC, Shusharina NP, Wang Y, Veeraraghavan H, Thor M, Muren LP, Rao SS, Lee NY, Deasy JO

  • Phys Med Biol. 2014 Feb 7;59(3):733-46.

2014-02-28

Fig 1. A right-posterior (45°) view of an example delineated trigone (cyan), defined as the triangle-shaped structure between the transition of the urethra surrogate structure (light yellow) into the bladder wall (dark yellow) caudally and the transition of the distal ureters (magenta) in the bladder wall cranially. The planning target volume is depicted in red.

Fig 1. A right-posterior (45°) view of an example delineated trigone (cyan), defined as the triangle-shaped structure between the transition of the urethra surrogate structure (light yellow) into the bladder wall (dark yellow) caudally and the transition of the distal ureters (magenta) in the bladder wall cranially. The planning target volume is depicted in red.
  • Ghadjar P, Zelefsky MJ, Spratt DE, Munck Af Rosenschöld P, Oh JH, Hunt M, Kollmeier M, Happersett L, Yorke E, Deasy JO, Jackson A

  • Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):339-44.

2014-03-03

Fig 1.Comparison of the cumulative incidence of local failure in patients with non-small cell lung cancer primary versus others.

Fig 1.Comparison of the cumulative incidence of local failure in patients with non-small cell lung cancer primary versus others.
  • Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, Chan TA, Lymberis SC, Narayana A, Tabar V, Gutin PH, Ballangrud A, Lis E, Beal K

  • Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):130-6.

2014-03-04

Fig 6. Model of Oct4 functions during preimplantation development.

Fig 6. Model of Oct4 functions during preimplantation development.
  • Le Bin GC, Muñoz-Descalzo S, Kurowski A, Leitch H, Lou X, Mansfield W, Etienne-Dumeau C, Grabole N, Mulas C, Niwa H, Hadjantonakis AK, Nichols J.

  • Development. 2014 Mar;141(5):1001-10
Open Access button

2014-03-05

Fig 1. Failure free survival based upon week 12 anatomic imaging assessment of response.

Fig 1. Failure free survival based upon week 12 anatomic imaging assessment of response.
  • Rosenberg A1, Anderson JR, Lyden E, Rodeberg DA, Wolden SL, Kao SC, Parham D6, Arndt C, Hawkins DS

  • Eur J Cancer. 2014 Mar;50(4):816-23

2014-03-06

Fig 1. Follicular lymphoma sample stained with (A) haematoxylin and eosin; (B) CD5, demonstrating multiple T cells in the inter-follicular area and (C) MIB-1, demonstrating follicles with proliferating tumour cells. Original magnification ×100.

Fig 1. Follicular lymphoma sample stained with (A) haematoxylin and eosin; (B) CD5, demonstrating multiple T cells in the inter-follicular area and (C) MIB-1, demonstrating follicles with proliferating tumour cells. Original magnification ×100.
  • Kedmi M1, Hedvat CV, Maragulia J, Zhang Z, Zelenetz AD

  • Br J Haematol. 2014 Mar;164(5):646-52.

2014-03-07

Fig 3. The Shroom actin-binding protein is planar polarized in intercalating cells. (A and B) Localization of Shroom (A–B) and Baz/Par-3 (A′ and B) in wild-type embryos at the indicated stages. (A) Anterior is left, and ventral is down. (B) Cross section of a stage 8 embryo, with apical up.

Fig 3. The Shroom actin-binding protein is planar polarized in intercalating cells. (A and B) Localization of Shroom (A–B) and Baz/Par-3 (A′ and B) in wild-type embryos at the indicated stages. (A) Anterior is left, and ventral is down. (B) Cross section of a stage 8 embryo, with apical up.
  • Simões Sde M, Mainieri A, Zallen JA

  • J Cell Biol. 2014 Feb 17;204(4):575-89

2014-03-10

Fig 2. A model of clonal origins of neocortical interneuron diversity and distribution. (a) RGPs in the VZ of the MGE are likely heterogeneous in proliferative behavior and neurogenesis potential.

Fig 2. A model of clonal origins of neocortical interneuron diversity and distribution. (a) RGPs in the VZ of the MGE are likely heterogeneous in proliferative behavior and neurogenesis potential.
  • Sultan KT, Shi W, Shi SH

  • Curr Opin Neurobiol. 2014 Feb 12;26C:125-131

2014-03-11

Fig 1. Kaplan–Meier estimates of overall survival (OS; a) and radiographic progression-free survival (rPFS; b) in the subsets with and without visceral disease at baseline. AA, abiraterone acetate; P, prednisone; VD, visceral disease; atest of homogeneity of the 4 subgroups.

Fig 1. Kaplan–Meier estimates of overall survival (OS; a) and radiographic progression-free survival (rPFS; b) in the subsets with and without visceral disease at baseline. AA, abiraterone acetate; P, prednisone; VD, visceral disease; atest of homogeneity of the 4 subgroups.
  • Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI

  • Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9
Open Access button

2014-03-12

Fig 1. Percentage of patients undergoing completion lymph node dissection (CLND) following a positive SLNB by date of surgery (1996–2001 (n = 11), 2002–2006 (n = 18), 2007–2012 (n = 25)) – all patients and the subgroup of patients with only micrometastatic disease (<0.2 mm) in the SLN.

Fig 1. Percentage of patients undergoing completion lymph node dissection (CLND) following a positive SLNB by date of surgery (1996–2001 (n = 11), 2002–2006 (n = 18), 2007–2012 (n = 25)) – all patients and the subgroup of patients with only micrometastatic disease (<0.2 mm) in the SLN.
  • Gyorki DE, Boyle JO, Ganly I, Morris L, Shaha AR, Singh B, Wong R, Shah JP, Busam K, Kraus D, Coit DG, Patel S

  • Eur J Surg Oncol. 2014 Mar;40(3):305-10

2014-03-13

Fig 1. Use of operative drains and grade >=3 fistula rates. Lines: Prophylactic drainage trends over years per surgeon type. Bars: Incidence of grade >=3 fistula overall. RD, routine drainers; SD, selective drainers; ND, nondrainers.

Fig 1. Use of operative drains and grade >=3 fistula rates. Lines: Prophylactic drainage trends over years per surgeon type. Bars: Incidence of grade >=3 fistula overall. RD, routine drainers; SD, selective drainers; ND, nondrainers.
  • Correa-Gallego C, Brennan MF, Dʼangelica M, Fong Y, Dematteo RP, Kingham TP, Jarnagin WR, Allen PJ

  • Ann Surg. 2013 Dec;258(6):1051-8.

2014-03-14

Neuroblastoma; Biomarker; Zinc-alpha2-glycoprotein; Complement C3; TH-MYCN+/+; Complement system

Neuroblastoma; Biomarker; Zinc-alpha2-glycoprotein; Complement C3; TH-MYCN+/+; Complement system
  • Kim PY, Tan O, Diakiw SM, Carter D, Sekerye EO, Wasinger VC, Liu T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, Cheung BB

  • J Proteomics. 2013 Nov 4;96C:1-12.

2014-03-17

(a) Prostate cancer-specific mortality and (b) death from competing causes after radical prostatectomy, stratified by the presence of positive and negative surgical margins.

(a) Prostate cancer-specific mortality and (b) death from competing causes after radical prostatectomy, stratified by the presence of positive and negative surgical margins.
  • Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT

  • Eur Urol. 2014 Apr;65(4):675-80.

2014-03-18

Kaplan-Meier curves of progression-free survival (by central analysis)

Kaplan-Meier curves of progression-free survival (by central analysis)
  • Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B

  • Lancet Oncol. 2014 Mar;15(3):286-96.

2014-03-19

Fig 1. Protein dimer bound to DNA.

Fig 1. Protein dimer bound to DNA.
  • Ptashne M

  • J Biol Chem. 2014 Feb 28;289(9):5417-35.

2014-03-20

Fig 1. Graphical abstract.

Fig 1. Graphical abstract.
  • Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, Massagué J

  • Cell. 2014 Feb 27;156(5):1002-16.

2014-03-21

Fig 1. Graphical abstract.

Fig 1. Graphical abstract.
  • Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF

  • Cell. 2014 Feb 27;156(5):986-1001.

2014-03-24

Fig 1. Tumor Response 4 to 8 Weeks Post SIRT as Assessed by Reduction in Tumor Size (RECIST), Decrease in Metabolic Activity (PERCIST) or Tumor Marker (CEA).

Fig 1. Tumor Response 4 to 8 Weeks Post SIRT as Assessed by Reduction in Tumor Size (RECIST), Decrease in Metabolic Activity (PERCIST) or Tumor Marker (CEA).
  • Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE

  • Clin Colorectal Cancer. 2014 Mar;13(1):27-36.

2014-03-25

Fig 1. PSA relapse-free survival. PSA = prostate-specific antigen; HDR = high-dose-rate brachytherapy.

Fig 1. PSA relapse-free survival. PSA = prostate-specific antigen; HDR = high-dose-rate brachytherapy.
  • Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen GN, Donat SM, Cox BW, Zelefsky MJ

  • Brachytherapy. 2014 Mar-Apr;13(2):111-6.

2014-03-26

Fig 1. Graphical abstract.

Fig 1. Graphical abstract.
  • Rodriguez-Bravo V, Maciejowski J, Corona J, Buch HK, Collin P, Kanemaki MT, Shah JV, Jallepalli PV

  • Cell. 2014 Feb 27;156(5):1017-31.

2014-03-27

Graphical Abstract

Graphical Abstract
  • Simanshu DK, Zhai X, Munch D, Hofius D, Markham JE, Bielawski J, Bielawska A, Malinina L, Molotkovsky JG, Mundy JW8, Patel DJ, Brown RE

  • Cell Rep. 2014 Jan 30;6(2):388-99.
Open Access button

2014-03-28

Graphical Abstract.

Graphical Abstract.
  • Chudnovsky Y, Kim D, Zheng S, Whyte WA, Bansal M, Bray MA, Gopal S, Theisen MA, Bilodeau S, Thiru P, Muffat J, Yilmaz OH, Mitalipova M, Woolard K, Lee J, Nishimura R, Sakata N, Fine HA, Carpenter AE, Silver SJ, Verhaak RG, Califano A, Young RA, Ligon KL, Mellinghoff IK, Root DE, Sabatini DM, Hahn WC, Chheda MG

  • Cell Rep. 2014 Jan 30;6(2):313-24.
Open Access button

2014-03-31

Overall survival by arm.

Overall survival by arm.
  • Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR

  • Leuk Res. 2014 Mar;38(3):329-33.

2014-04-01

Fig 3. Multiple patterns of AR gain and amplification found in a single TMA core.

Fig 3. Multiple patterns of AR gain and amplification found in a single TMA core.
  • Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G, Berney DM, Foster CS, Møller H, Scardino P, Cuzick J, Cooper CS, Clark JP on behalf of the Transatlantic Prostate Group

  • Br J Cancer. 2014 Mar 18;110(6):1655-62